Pharm
Tetracyclines
search
Tetracyclines
, Tetracycline Antibiotic, Naphthacene
See Also
Doxycycline
Eravacycline
Tetracycline
Minocycline
Omadacycline
Sarecycline
Tigecycline
Democycline
Indications
Skin disorders
Methicillin
-Resistant
Staphylococcus aureus
(
MRSA
)
Skin Infection
s
Acne Vulgaris
Acne Rosacea
Gastrointestinal disorders
Helicobacter Pylori
(part of quadruple therapy protocol)
Tick-borne illness
Lyme Disease
Human Granulocytic Anaplasmosis
(
Human Granulocytic Ehrlichiosis
)
Rocky Mountain Spotted Fever
Miscellaneous disorders
Community Acquired Pneumonia
Malaria Prophylaxis
Sexually Transmitted Disease
Chlamydia trachomatis
Lymphogranuloma venereum
Contraindications
Pregnancy
Pregnancy category D
Children under age 8 years old
AAP now approves
Doxycycline
for ANY age up to 21 day duration
Unlike
Tetracycline
,
Doxycycline
is unlikely to cause visible tooth staining
For severe infections (e.g.
Lyme Disease
,
Rocky Mountain Spotted Fever
),
Doxycycline
is a first-line agent
Mechanism
Tetracyclines are bacteriostatic, semi-synthetic, broad-spectrum Naphthacene
Antibiotic
s produced by Streptomyces species
Tetracyclines inhibit
Bacteria
l
Protein
synthesis
Binds to
Bacteria
l 30S ribosomal subunit of susceptible
Bacteria
Blocks aminoacyl-tRNA binding to the mRNA-ribosome complex (ribosomal A site)
Prevents elongated peptide chains from forming from
Amino Acid
residues
Medications
Oral and Topical Agents
Tetracycline
See
Tetracycline
Acne Vulgaris
: 1 gram orally daily given in 2-4 divided doses
Doxycycline
See
Doxycycline
Typical dose: 100 mg orally twice daily
Low doses, such as 50 mg daily, are often as effective for acne
Avoid substituting low-dose
Doxycycline
(Periostat, Oracea) products for systemic infections
Minocycline
(
Minocin
)
Oral
Acne Vulgaris
: 50-200 mg/d orally in divided doses
Topicals
Acne Vulgaris
:
Minocycline
4% Foam (Amzeeq)
Rosacea
:
Minocycline
1.5% Foam (Zilxi)
Very expensive (nearly $500 for 30 grams)
No evidence of benefit over other
Rosacea
topicals
(2021) Presc Lett 28(6): 36 [PubMed]
Medications
Intravenous
Eravacycline
(
Xerava
)
Omadacycline
(
Nuzyra
)
Load: 200 mg IV for one dose (or divided 100 mg IV every 12 hours for 2 doses)
Maintenance: 100 mg IV once daily (or 300 mg orally once daily)
Once daily agent indicated for
Community Acquired Pneumonia
and
Skin Infection
s
Released in 2018 at $400 per pill, and likely less effective than standard agents for CAP
(2019) presc lett 26(1):4
Drug Interactions
Food Related
Tetracycline
Milk and
Calcium
-rich food decrease absorption
Take 1 hour before or 2 hours after a meal
Doxycycline
and
Minocycline
Can be taken with milk or food (unlike
Tetracycline
)
Take with a full glass of water
Risk of
Pill Esophagitis
Warfarin
Increases INR
Precautions
Use
Sunscreen
with these agents due to
Drug-induced Photosensitivity
Pill Esophagitis
Take with a full glass of water
Adverse Effects
Gene
ral
Pseudotumor Cerebri
(rare)
Pill Esophagitis
Tetracycline
Photosensitivity
Interferes with OCP action
Tooth Discoloration
(Children under age 8 years)
Tooth
enamel hypoplasia
Rare with
Doxycycline
Doxycycline
Photosensitivity
Abdominal Pain
Diarrhea
Pill Esophagitis
(see above)
Minocycline
Gene
rally well tolerated
Does not generally cause photosensitivity
Minocycline-Induced Hyperpigmentation
Blue-gray or muddy brown
Hyperpigmentation
resulting from
Minocycline
-iron complex skin deposition
Distribution: Face, arms, legs (esp. shins)
Highest risk in long-term dosing for chronic infection or
Rheumatoid Arthritis
(risk increases with longer duration)
Uncommon with low dose
Acne Vulgaris
use
Hyperpigmentation
often persists even after
Minocycline
is discontinued (limited therapies, e.g. laser)
Jain (2019) Am Fam Physician 100(4): 239-240 [PubMed]
Rare adverse effects
Lupus-Like Syndrome
(1:20,000)
Vertigo
Oral Mucosa
pigmentation (blue-black pigmentation)
Hypersensitivity
Syndrome within 1-3 months
Delayed
Arthralgia
s or
Polyarthritis
Omadacycline
(
Nuzyra
)
Nausea
and
Vomiting
are most common (>10% of patients)
References
(2019) Tarascon Pharmacopeia, accessed 3/31/2019
LoVecchio (2019) Crit Dec Emerg Med 33(3): 28
Type your search phrase here